Brief: Anavex Life Sciences Announces Continued Long-Term Benefit From Oral Blarcamesine In Alzheimer’s Disease
29/10/2025 12:50
Oct 29 (Reuters) - Anavex Life Sciences Corp AVXL.O: ANAVEX LIFE SCIENCES ANNOUNCES CONTINUED LONG-TERM BENEFIT FROM ORAL BLARCAMESINE COMPARED TO DECLINE OBSERVED IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) CONTROL GROUP ANAVEX LIFE SCIENCES CORP - BLARCAMESINE SHOWS FAVORABLE SAFETY PROFILE WITH NO TREATMENT-RELATED DEATHS ANAVEX LIFE SCIENCES CORP - BLARCAMESINE CONFIRMED TO RESTORE IMPAIRED AUTOPHAGY ANAVEX LIFE SCIENCES CORP - 77.4 WEEKS 'TIME SAVED' WITH BLARCAMESINE COMPARED TO ADNI Source text: ID:nGNX80lBxC Further company coverage: AVXL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board